Proven Antifungal Efficacy That Cures With QD Use^1,2

For your patients with Tinea Pedia, Cruris, and Corporis real life demands once-daily convenience.

• Excellent clinical response to once-daily therapy (P,0.05)^1,2 - 80% mycological cure rate at 2 weeks post-treatment²
• Relief of erythema at 1 week (P=0.008)¹
• Convenient QD dosing,¹ to minimize disruption to patient lifestyle
• OXISTAT^® (oxicanazole nitrate) cream is safe for pediatric use.¹

Available in 60-g, 30-g, and 15-g tubes; 30-mil. bottle. Efficacy made easy.

The most common adverse events with OXISTATcream in clinical studies in adults (n=955)were less than 2%,including pruritus (1.6%) and burning(1.4%).The most common adverse events with OXISTATlotion in clinical studies (n=269) were pruritus and burning which were less than 1%.

For complete Prescribing Information, click here.

References: 1. OXISTATPrescribing Information. 2. Ellis CN, Gammon WR, Goldfarb MT, et al. A placebo-controlled evaluation of once-daily versus twice-daily oxiconazole nitrate (1%) cream in the treatment of tinea pedis. Curr Ther Res. 1989;46:269-276. 3. Elewski BE, Jones T, Zaias N. Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis. Cutis. 1996;58:305-307.